Join Us Live or Online for the Miami MCRT on January 22
Join Us Live or Online for the Miami MCRT on January 22
Join Us Live or Online for the Miami MCRT on January 22
C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and…
C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and…
C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and…
On 12th April 2024, a meeting of the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) was held to assess the use…
The Committee will discuss the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding t…
The Miami Myeloma MRD Meeting 2024 brings together leading experts to discuss measurable residual disease (MRD) for multiple myeloma.
Dr. Ola Landgren will discuss emerging myeloma therapies and clinical trials and the latest options for relapsed disease.
Benjamin Diamond, M.D., a hematologist-oncologist who specializes in multiple myeloma at Sylvester Comprehensive Cancer Center, explains what multiple myelom…
The DCC is a year-round collective community movement to raise money in support of Sylvester Comprehensive Cancer Center at the University of Miami. With your…